Testing the diagnostic accuracy of a 68Ga-PSMA PET Scan in Early Biochemical Recurrence of Prostate Cancer
PET-PSMA is currently used for restaging prostate cancer (pCa) after primary surgery or radiotherapy. The PSA levels beyond which it is useful to perform it, in terms of cost-benefit ratio, are not to date clearly defined.
Saved in:
| Main Authors: | Vigna-Taglianti Riccardo, Boriano Alberto, Martini Stefania, Olivero Francesco, Solla Salvatore, Spinelli Lavinia, Gianello Luca, Peano Simona, Merlotti Anna Maria |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2024-10-01
|
| Series: | Forum of Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/fco-2023-0034 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An Evaluation of the Diagnostic Accuracy of [68Ga]Ga-PSMA-11 vs. [18F]F-PSMA-1007 PET/CT for Lymph Node Staging in Patient Candidates for Radical Prostatectomy and Lymph Node Dissection: A Single Institutional Analysis
by: Paola Arena, et al.
Published: (2025-06-01) -
Does total lesion prostate‐specific membrane antigen (PSMA) activity on 68Ga‐PSMA PET/CT correlate with PSA and prostatectomy histopathological/clinical outcomes in patients with localised primary prostate cancer?
by: Jeremy Cheng, et al.
Published: (2025-04-01) -
Indications and Results for Ga-68 PSMA PET/CT in Patients with Biochemical Relapse of Prostate Cancer
by: Ivan Rogić, et al.
Published: (2024-01-01) -
Comparing the Diagnostic Performance of [18F]PSMA‐1007 With [68Ga]Ga‐PSMA‐11 in PET/CT Imaging and Staging of Recurrent Prostate Cancer
by: Negar Abdi, et al.
Published: (2025-03-01) -
Imply on diagnosis and early prognosis of preoperative [68Ga]Ga-PSMA-11 PET/CT in patients with suspected brain tumours of glial origin
by: K. Pełka, et al.
Published: (2025-01-01)